CagriSema is a fixed-dose combination therapy comprising two molecules administered together in a single once-weekly subcutaneous injection: semaglutide 2.4 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist already approved for weight management as Wegovy, and cagrilintide 2.4 mg, a long-acting analogue of amylin, a hormone involved in appetite regulation and satiety signalling
It activates genes involved in collagen synthesis, anti-inflammatory responses, and stem cell recruitment
For patients considering peptide therapy, the safest option is to work with a licensed provider who can evaluate your health history, order appropriate lab work, and recommend a treatment plan based on your goals
Keep realistic goals and small wins: track improvements in sleep, diet, and lab markers rather than fixating on a single cycle
Zhang Y, Zhang S, Li B, Luo Y, Gong Y, Jin X, Zhang J, Zhou Y, Zhuo X, Wang Z, Zhao X, Han X, Gao Y, Yu H, Liang D, Zhao S, Sun D, Wang D, Xu W, Qu G, Bo W, Li D, Wu Y, Li Y